Sexual Dysfunction and Metabolic/Hormonal Changes in Women Using Long-Term Hormonal and Non-Hormonal Contraceptives

Background Female sexual dysfunction is a common condition that negatively impacts the emotional health and quality of life of the affected individuals. Long-acting reversible contraceptives (LARCs) are becoming increasingly popular due to their effectiveness and convenience. LARCs can be hormonal (etonogestrel releasing implant—ENG and Levonorgestrel intrauterine system—LNG) or non-hormonal (copper intrauterine device—CuIUD and copper-silver intrauterine device—SIUD). There are very few studies that assess the influence on LARCS on sexual function are lacking.This study aimed to assess changes in sexual function as well as metabolic and hormonal parameters in women after implantation with LARCs. Methods In this prospective cohort study, we assessed 80 women who visited the Military Police Hospital in Brazil for LARCs placement. The study participants were divided into 4 groups according to the type of LARC received: ENG n = 17; LNG n = 21, CuIUD n = 18 and SIUD n = 23. The four groups were evaluated twice (prior to LARC placement and approximately 3 months later) for sexual function, using the Female Sexual Function Index (FSFI) and Female Sexual Quotient (QS-F) questionnaires. Metabolic and hormonal parameters were also assessed using blood tests. p < 0.05 was considered to indicate statistical significance. Results We observed an improvement in sexual function with CuIUD placement according to QS-F (p < 0.017) and SIUD (FSFI: p = 0.06 and QS-F: p < 0.001). However, ENG worsened sexual function according to FSFI and QS-F (p < 0.001 and p = 0.003), across all domains. A decrease in sex hormone-binding globulin (SHBG) was observed for all groups (LNG: p = 0.019; ENG: p = 0.024; CuIUD: p = 0.010; SIUD: p = 0.022) and an increase in total testosterone levels (p = 0.007 and p = 0.003) and prolactin (p = 0.049 and p = 0.001) with CuIUD and SIUD placement. Hemoglobin levels increased with LIS (p < 0.001) and ENG (p = 0.025) and decreased with CuIUD placement (p < 0.001). Conclusion The use of non-hormonal LARCS improved sexual function, especially in the desire domain. Etonogestrel implants, had a negative influence on sexual function, probably by blocking ovarian function, and thus reducing the production of androgens and estrogens. SIUD placement was superior as it improved sexual function, interfered less with hormonal levels, and did not decrease hemoglobin levels.

[1]  A. Montejo,et al.  Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review , 2019, Journal of clinical medicine.

[2]  S. Skouby,et al.  Impact of progestogens on hemostasis , 2018, Hormone molecular biology and clinical investigation.

[3]  J. Higgins,et al.  The Impact of Sexual Satisfaction, Functioning, and Perceived Contraceptive Effects on Sex Life on IUD and Implant Continuation at 1 Year. , 2018, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[4]  O. Michael,et al.  Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy , 2018, Archives of physiology and biochemistry.

[5]  F. Nahidi,et al.  Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis , 2018, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[6]  Long-Acting Reversible Contraception : Implants and Intrauterine Devices , 2017 .

[7]  P. Hannaford,et al.  Contemporary Hormonal Contraception and the Risk of Breast Cancer , 2017, The New England journal of medicine.

[8]  Camila Soares Lima Corrêa,et al.  Rastreamento do câncer do colo do útero em Minas Gerais: avaliação a partir de dados do Sistema de Informação do Câncer do Colo do Útero (SISCOLO) , 2017 .

[9]  L. Low,et al.  Oral Contraception and Female Sexual Dysfunction in Reproductive Women , 2017 .

[10]  M. Palta,et al.  Women's Sexual Function, Satisfaction, and Perceptions After Starting Long-Acting Reversible Contraceptives , 2016, Obstetrics and gynecology.

[11]  J. Higgins,et al.  The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept , 2016, Journal of sex research.

[12]  J. Peipert,et al.  Sexual Desire and Hormonal Contraception , 2016, Obstetrics and gynecology.

[13]  B. Okopień,et al.  The effect of oral contraception on macroprolactin levels in women with macroprolactinemia: A pilot study. , 2015, Pharmacological reports : PR.

[14]  J. Higgins,et al.  Contraceptive sex acceptability: a commentary, synopsis and agenda for future research. , 2014, Contraception.

[15]  P. Inki,et al.  Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study , 2014, Human reproduction.

[16]  S. Sanders,et al.  Hormonal contraception and female pain, orgasm and sexual pleasure. , 2014, The journal of sexual medicine.

[17]  G. Bifulco,et al.  Impact of an implantable steroid contraceptive (etonogestrel-releasing implant) on quality of life and sexual function: a preliminary study , 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[18]  K. Curtis,et al.  Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. , 2013, Contraception.

[19]  S. Christin‐Maitre,et al.  History of oral contraceptive drugs and their use worldwide. , 2013, Best practice & research. Clinical endocrinology & metabolism.

[20]  L. Burrows,et al.  The effects of hormonal contraceptives on female sexuality: a review. , 2012, The journal of sexual medicine.

[21]  I. Kaygusuz,et al.  Etonogestrel contraceptive implant (Implanon): analysis of patient compliance and adverse effects in the breastfeeding period. , 2010, Journal of the Turkish German Gynecological Association.

[22]  J. Peipert,et al.  The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. , 2010, American journal of obstetrics and gynecology.

[23]  B. Kaneshiro,et al.  Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device , 2010, International journal of women's health.

[24]  Kuldip Singh,et al.  Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism--a randomized comparative study. , 2009, Contraception.

[25]  D. Mansour Modern management of abnormal uterine bleeding: the levonorgestrel intra-uterine system. , 2007, Best practice & research. Clinical obstetrics & gynaecology.

[26]  J. Higgins,et al.  The pleasure deficit: revisiting the "sexuality connection" in reproductive health. , 2007, International family planning perspectives.

[27]  L. Camano,et al.  Validação do índice da função sexual feminina em grávidas brasileiras , 2007 .

[28]  P. Touraine,et al.  Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. , 2007, Annales d'endocrinologie.

[29]  M. Çolakoğlu,et al.  Contraceptive efficacy and side effects of Implanon® , 2007, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[30]  I. Goldstein,et al.  Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. , 2006, The journal of sexual medicine.

[31]  Heloisa Junqueira Fleury,et al.  Aspectos diagnósticos e terapêuticos das disfunções sexuais femininas , 2006 .

[32]  C. Abdo Elaboração e validação do quociente sexual - versão feminina: uma escala para avaliar a função sexual da mulher , 2006 .

[33]  J. Warnock,et al.  Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women , 2005, Menopause.

[34]  E. Moreira,et al.  Prevalence of sexual dysfunctions and correlated conditions in a sample of Brazilian women—results of the Brazilian study on sexual behavior (BSSB) , 2004, International Journal of Impotence Research.

[35]  K. Curtis,et al.  Contraception for Women in Selected Circumstances , 2002, Obstetrics and gynecology.

[36]  H. Burger,et al.  Hormones, mood, sexuality, and the menopausal transition. , 2002, Fertility and sterility.

[37]  R. Basson Human Sex-Response Cycles , 2001, Journal of sex & marital therapy.

[38]  Candace S. Brown,et al.  The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. , 2000, Journal of sex & marital therapy.

[39]  I. Rauramo,et al.  Two-year clinical experience with Nova-T 380, a novel copper–silver IUD , 1999, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[40]  E. Faragher,et al.  An analysis of the corrosion process of the nova-T IUD , 1994, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

[41]  O. Borggaard,et al.  Copper release from copper intrauterine devices removed after up to 8 years of use. , 1993, Contraception.

[42]  E. A. Mezhevitinova,et al.  [Intrauterine contraception]. , 1993, Akusherstvo i ginekologiia.

[43]  F. Gabino,et al.  Basal and metoclopramide-stimulated prolactin (PRL) serum levels in users and non-users of a copper intrauterine device (TCu-380 IUD). , 1991, Contraception.

[44]  R. Chapman,et al.  Serum prolactin concentrations related to copper or inert intrauterine devices (IUDs) in women. , 1979, Contraception.

[45]  E. Kesserü,et al.  Copper IUD: enhancement of its efficacy by the addition of silver and nickel. , 1974, Contraception.